| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $13.1M | — | +3.1% |
| SG&A Expense | $6.7M | — | +59.3% |
| Operating Income | -$19.8M | — | -17.0% |
| Net Income | -$18.1M | — | -18.0% |
| EPS (Basic) | -$0.18 | — | +18.2% |
| EPS (Diluted) | -$0.18 | — | +18.2% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $9.1M | -90.3% | -13.1% |
| Short-term Investments | $143.1M | +94.0% | +46.3% |
| Current Assets | $154.7M | -9.6% | +40.4% |
| Total Assets | $158.7M | -9.6% | +28.6% |
| Current Liabilities | $10.2M | -14.3% | +27.8% |
| Total Liabilities |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$17.4M | — | -8.8% |
| Investing Cash Flow | -$68.5M | — | -38.6% |
| Financing Cash Flow | $911K | — | -83.4% |
| $11.5M |
| -14.0% |
| +15.3% |
| Stockholders' Equity | $147.2M | -9.2% | +29.7% |